The aprotinin saga and the risks of conducting meta-analyses on small randomised controlled trials - A critique of a Cochrane review

BMC Health Services Research

Volumn 9, Issue , 2009, Pages

  Rosén, Måns ^a  

^a Swedish Council on Technology Assessment in Health Care   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

APROTININ; HEMOSTATIC AGENT;

ARTICLE; COCHRANE LIBRARY; FOLLOW UP; HUMAN; META ANALYSIS; MORTALITY; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PROSPECTIVE STUDY; QUALITY CONTROL; BLEEDING; LETTER; POSTMARKETING SURVEILLANCE; RANDOMIZED CONTROLLED TRIAL; SAMPLE SIZE; TREATMENT OUTCOME; TREATMENT WITHDRAWAL;

APROTININ; BLOOD LOSS, SURGICAL; HEMOSTATICS; HUMANS; META-ANALYSIS AS TOPIC; PRODUCT SURVEILLANCE, POSTMARKETING; QUALITY CONTROL; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SAMPLE SIZE; TREATMENT OUTCOME; WITHHOLDING TREATMENT;

EID: 62749100069     PISSN: None     EISSN: 14726963     Source Type: Journal    
DOI: 10.1186/1472-6963-9-34     Document Type: Article

References (23)

1. A comparison of aprotinin and lysine analogues in high-risk cardiac surgery. DA Fergusson PC Hébert CD Mazer S Fremes C MacAdams JM Murkin K Teoh PC Duke R Arellano MA Blajchman JS Bussières D Cǒté J Karski R Martineau JA Robblee M Rodger G Wells J Clinch R Pretorius BART Investigators, N Engl J Med 2008 358 22 2319 2331 10.1056/NEJMoa0802395 18480196
2. Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion. DA Henry PA Carless AJ Moxey D O'Connell BJ Stokes B McClelland A Laupacis D Fergusson, Cochrane Database Syst Rev 2007 4 CD001886 17943760
3. Pharmacological strategies to decrease excessive blood loss in cardiac surgery: a meta-analysis of clinically relevant endpoints. M Levi ME Cromheecke E de Jonge MH Prins BJ de Mol E Briet HR Buller, Lancet 1999 354 9194 1940 1947 10.1016/S0140-6736(99)01264-7 10622296
4. Effect of aprotinin on clinical outcomes in coronary artery bypass graft surgery: a systematic review and meta-analysis of randomized clinical trials. A Sedrakyan T Treasure JA Elefteriades, J Thorac Cardiovasc Surg 2004 128 3 442 448 10.1016/j.jtcvs.2004.03.041 15354106
5. A propensity score case-control comparison of aprotinin and tranexamic acid in high-transfusion-risk cardiac surgery. K Karkouti WS Beattie KM Dattilo SA McCluskey M Ghannam A Hamdy DN Wijeysundera L Fedorko TM Yau, Transfusion 2006 46 3 327 338 10.1111/j.1537-2995.2006.00724.x 16533273
6. Mortality associated with aprotinin during 5 years following coronary artery bypass graft surgery. DT Mangano Y Miao A Vuylsteke IC Tudor R Juneja D Filipescu A Hoeft ML Fontes Z Hillel E Ott T Titov C Dietzel J Levin Investigators of The Multicenter Study of Perioperative Ischemia Research Group; Ischemia Research and Education Foundation, JAMA 2007 297 5 471 479 10.1001/jama.297.5.471 17284697
7. The risk associated with aprotinin in cardiac surgery. DT Mangano IC Tudor C Dietzel, N Engl J Med 2006 354 4 353 365 10.1056/NEJMoa051379 16436767
8. Aprotinin during coronary-artery bypass grafting and risk of death. S Schneeweiss JD Seeger J Landon AM Walker, N Engl J Med 2008 358 8 771 783 10.1056/NEJMoa0707571 18287600
9. The effect of aprotinin on outcome after coronary-artery bypass grafting. AD Shaw M Stafford-Smith WD White B Phillips-Bute M Swaminathan C Milano IJ Welsby S Aronson JP Mathew ED Peterson MF Newman, N Engl J Med 2008 358 8 784 793 10.1056/NEJMoa0707768 18287601
10. Putting clinical trials into context. C Young R Horton, Lancet 2005 366 9480 107 108 10.1016/S0140-6736(05)66846-8 16005318
11. High-dose aprotinin in cardiac surgery: three years' experience in 1,784 patients. W Dietrich A Barankay C Hahnel JA Richter, J Cardiothorac Vasc Anesth 1992 6 3 324 327 10.1016/1053-0770(92)90150-6 1377036
12. Long-term clinical outcome in the Bypass Angioplasty Revascularization Investigation Registry: comparison with the randomized trial. BARI Investigators. F Feit MM Brooks G Sopko NM Keller A Rosen R Krone PB Berger R Shemin MJ Attubato DO Williams R Frye KM Detre, Circulation 2000 101 24 2795 2802 10859284
13. 13-year follow-up of the German angioplasty bypass surgery investigation. J Kaehler R Koester W Billmann C Schroeder HJ Rupprecht T Ischinger R Jahns A Vogt M Lampen R Hoffmann R Riessen J Berger T Meinertz CW Hamm, Eur Heart J 2005 26 20 2148 2153 10.1093/eurheartj/ehi385 15975991
14. Large trials vs meta-analysis of smaller trials: how do their results compare? JC Cappelleri JP Ioannidis CH Schmid SD de Ferranti M Aubert TC Chalmers J Lau, JAMA 1996 276 16 1332 1338 10.1001/jama.276.16.1332 8861993
15. Issues in comparisons between meta-analyses and large trials. JP Ioannidis JC Cappelleri J Lau, JAMA 1998 279 14 1089 1093 10.1001/jama.279.14. 1089 9546568
16. Discrepancies between meta-analyses and subsequent large randomized, controlled trials. J LeLorier G Gregoire A Benhaddad J Lapierre F Derderian, N Engl J Med 1997 337 8 536 542 10.1056/NEJM199708213370806 9262498
17. Reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses. LL Kjaergard J Villumsen C Gluud, Ann Intern Med 2001 135 11 982 989 11730399
18. Learning from aprotinin - mandatory trials of comparative efficacy and safety needed. WA Ray, N Engl J Med 2008 358 8 840 842 10.1056/NEJMe0800268 18287607
19. Meta-analysis comparing the effectiveness and adverse outcomes of antifibrinolytic agents in cardiac surgery. JR Brown NJ Birkmeyer GT O'Connor, Circulation 2007 115 22 2801 2813 10.1161/CIRCULATIONAHA.106.671222 17533182
20. The safety of aprotinin and lysine-derived antifibrinolytic drugs in cardiac surgery: a meta-analysis. DA Henry P Carless D Fergusson A Laupacis, CMAJ 2009 180 2 19050037
21. Death and Renal Dysfunction with Aprotinin Use in Cardiac Surgery: A Meta-Analysis of Observational Studies. JJ Gagne DEG Griesdale S Schneeweiss, 24th International Conference on Pharmacoepidemiology & Therapeutic Risk Management Copenhagen, Denmark 2008
22. The aprotinin story - Is BART the final chapter? WA Ray CM Stein, N Engl J Med 2008 358 2398 400 10.1056/NEJMe0803514 18480197
23. Development of AMSTAR: a measurement tool to assess the methodological quality of systematic reviews. BJ Shea JM Grimshaw GA Wells M Boers N Andersson C Hamel AC Porter P Tugwell D Moher LM Bouter, BMC Med Res Methodol 2007 7 10 17302989 10.1186/1471-2288-7-10